JP2015525208A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525208A5
JP2015525208A5 JP2015514144A JP2015514144A JP2015525208A5 JP 2015525208 A5 JP2015525208 A5 JP 2015525208A5 JP 2015514144 A JP2015514144 A JP 2015514144A JP 2015514144 A JP2015514144 A JP 2015514144A JP 2015525208 A5 JP2015525208 A5 JP 2015525208A5
Authority
JP
Japan
Prior art keywords
seq
isolated
purified
cancer
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525208A (ja
JP6378172B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042162 external-priority patent/WO2013177247A1/en
Publication of JP2015525208A publication Critical patent/JP2015525208A/ja
Publication of JP2015525208A5 publication Critical patent/JP2015525208A5/ja
Application granted granted Critical
Publication of JP6378172B2 publication Critical patent/JP6378172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514144A 2012-05-22 2013-05-22 マウス抗ny−eso−1t細胞受容体 Active JP6378172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650020P 2012-05-22 2012-05-22
US61/650,020 2012-05-22
PCT/US2013/042162 WO2013177247A1 (en) 2012-05-22 2013-05-22 Murine anti-ny-eso-1 t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018139890A Division JP2018196384A (ja) 2012-05-22 2018-07-26 マウス抗ny−eso−1 t細胞受容体

Publications (3)

Publication Number Publication Date
JP2015525208A JP2015525208A (ja) 2015-09-03
JP2015525208A5 true JP2015525208A5 (https=) 2016-06-02
JP6378172B2 JP6378172B2 (ja) 2018-08-22

Family

ID=48539439

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015514144A Active JP6378172B2 (ja) 2012-05-22 2013-05-22 マウス抗ny−eso−1t細胞受容体
JP2018139890A Pending JP2018196384A (ja) 2012-05-22 2018-07-26 マウス抗ny−eso−1 t細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018139890A Pending JP2018196384A (ja) 2012-05-22 2018-07-26 マウス抗ny−eso−1 t細胞受容体

Country Status (10)

Country Link
US (3) US9487573B2 (https=)
EP (3) EP2852613B1 (https=)
JP (2) JP6378172B2 (https=)
CN (2) CN104507963B (https=)
AU (1) AU2013266421B2 (https=)
CA (1) CA2874486C (https=)
ES (3) ES2718474T3 (https=)
IL (1) IL235720A0 (https=)
PT (2) PT3527584T (https=)
WO (1) WO2013177247A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2852613B1 (en) * 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2015113140A1 (en) * 2014-01-29 2015-08-06 University Health Network Methods and compositions for producing a cell expressing a t cell receptor
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
HK1248255A1 (zh) * 2015-06-24 2018-10-12 优瑞科生物技术公司 靶向ny-eso-1肽/mhc复合物的构建体及其用途
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ny−eso−1に結合するt細胞受容体およびその使用方法
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US10386882B2 (en) * 2017-04-14 2019-08-20 Allegro Microsystems, Llc Control circuit
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
JP7385556B2 (ja) 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Bcma抗原に特異的な免疫原性ペプチドおよびその使用
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
EP3749770B9 (en) 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
TWI822726B (zh) * 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Nyeso t細胞受體
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
CN110856751B (zh) 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
WO2020086647A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院(Dba西雅图儿童研究所) 抗二硝基苯酚的嵌合抗原受体
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2022055946A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
CN112375136B (zh) * 2020-11-03 2022-06-07 中国科学院微生物研究所 Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
US20250057949A1 (en) 2021-12-31 2025-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic T cell therapy with vaccination as a combination immunotherapy against cancer
WO2025077869A1 (en) * 2023-10-13 2025-04-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE533784T1 (de) * 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
CN1269412A (zh) * 2000-03-17 2000-10-11 国家人类基因组南方研究中心 一种新的人t细胞受体相关蛋白及其编码序列
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
EP2457928B1 (en) * 2007-03-13 2017-05-10 Universität Zürich Monoclonal human tumor-specific antibody
CA2700278A1 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP2852613B1 (en) * 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors

Similar Documents

Publication Publication Date Title
JP2015525208A5 (https=)
Burnett et al. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability
JP2015535816A5 (https=)
JP2017536825A5 (https=)
ES2989669T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
JP2018121657A5 (https=)
JP2014528714A5 (https=)
JP2018535647A5 (https=)
FI3688027T3 (fi) Mutatoidun p53:n tunnistavia t-solureseptoreita
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2018536393A5 (https=)
JP2012143232A5 (https=)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2015529641A5 (https=)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2012526542A5 (https=)
JP2017508475A5 (https=)
JP2012100677A5 (https=)
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
JP2016505635A5 (https=)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2013502913A5 (https=)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака